...
idya-img

Ideaya Biosciences Inc, Common Stock

IDYA

NSQ

$26.05

+$0.86

(3.41%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.18B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
710.66K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.86
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$24.71 L
$47.73 H
$26.05

About Ideaya Biosciences Inc, Common Stock

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIDYASectorS&P500
1-Week Return-6.06%-3.72%-0.05%
1-Month Return-0.53%-1.85%2.75%
3-Month Return-29.27%-11.4%7.4%
6-Month Return-30.64%-4.41%10.47%
1-Year Return-25.74%4.13%27.57%
3-Year Return24.17%0.3%29.56%
5-Year Return266.9%36.62%89.3%
10-Year Return132.8%106.81%206.09%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-19.54M27.94M50.93M23.39M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":38.36,"profit":true},{"date":"2021-12-31","value":54.86,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":45.92,"profit":true}]
Cost of Revenue1.25M39.70M1.73M2.10M4.01M[{"date":"2019-12-31","value":3.14,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":4.35,"profit":true},{"date":"2022-12-31","value":5.29,"profit":true},{"date":"2023-12-31","value":10.1,"profit":true}]
Gross Profit(1.25M)19.54M27.94M50.93M19.38M[{"date":"2019-12-31","value":-2.44,"profit":false},{"date":"2020-12-31","value":38.36,"profit":true},{"date":"2021-12-31","value":54.86,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":38.05,"profit":true}]
Gross Margin(Infinity%)100.00%100.00%100.00%82.86%[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":82.86,"profit":true}]
Operating Expenses44.27M54.88M78.21M113.43M157.81M[{"date":"2019-12-31","value":28.05,"profit":true},{"date":"2020-12-31","value":34.78,"profit":true},{"date":"2021-12-31","value":49.56,"profit":true},{"date":"2022-12-31","value":71.88,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(44.27M)(35.34M)(50.27M)(62.50M)(134.43M)[{"date":"2019-12-31","value":-4427100000,"profit":false},{"date":"2020-12-31","value":-3534400000,"profit":false},{"date":"2021-12-31","value":-5026800000,"profit":false},{"date":"2022-12-31","value":-6250200000,"profit":false},{"date":"2023-12-31","value":-13442900000,"profit":false}]
Total Non-Operating Income/Expense4.58M1.70M1.01M7.69M42.94M[{"date":"2019-12-31","value":10.68,"profit":true},{"date":"2020-12-31","value":3.95,"profit":true},{"date":"2021-12-31","value":2.36,"profit":true},{"date":"2022-12-31","value":17.92,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(41.98M)(34.49M)(49.76M)(58.66M)(112.96M)[{"date":"2019-12-31","value":-4197500000,"profit":false},{"date":"2020-12-31","value":-3449500000,"profit":false},{"date":"2021-12-31","value":-4976200000,"profit":false},{"date":"2022-12-31","value":-5865500000,"profit":false},{"date":"2023-12-31","value":-11296100000,"profit":false}]
Income Taxes(3.53M)(2.23M)(2.23M)(3.85M)3.84M[{"date":"2019-12-31","value":-92,"profit":false},{"date":"2020-12-31","value":-58.07,"profit":false},{"date":"2021-12-31","value":-58.1,"profit":false},{"date":"2022-12-31","value":-100.18,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(38.44M)(32.27M)(47.53M)(54.81M)(116.80M)[{"date":"2019-12-31","value":-3844200000,"profit":false},{"date":"2020-12-31","value":-3226500000,"profit":false},{"date":"2021-12-31","value":-4753100000,"profit":false},{"date":"2022-12-31","value":-5480800000,"profit":false},{"date":"2023-12-31","value":-11680110500,"profit":false}]
Income From Continuous Operations(41.98M)(34.49M)(49.76M)(58.66M)(112.96M)[{"date":"2019-12-31","value":-4197500000,"profit":false},{"date":"2020-12-31","value":-3449500000,"profit":false},{"date":"2021-12-31","value":-4976200000,"profit":false},{"date":"2022-12-31","value":-5865500000,"profit":false},{"date":"2023-12-31","value":-11296100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(38.44M)(32.27M)(47.53M)(54.81M)(112.96M)[{"date":"2019-12-31","value":-3844200000,"profit":false},{"date":"2020-12-31","value":-3226500000,"profit":false},{"date":"2021-12-31","value":-4753100000,"profit":false},{"date":"2022-12-31","value":-5480800000,"profit":false},{"date":"2023-12-31","value":-11296100000,"profit":false}]
EPS (Diluted)(4.13)(1.53)(1.39)(1.39)(1.97)[{"date":"2019-12-31","value":-413,"profit":false},{"date":"2020-12-31","value":-153,"profit":false},{"date":"2021-12-31","value":-139,"profit":false},{"date":"2022-12-31","value":-139,"profit":false},{"date":"2023-12-31","value":-197,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IDYA
Cash Ratio 22.63
Current Ratio 22.93

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IDYA
ROA (LTM) -15.85%
ROE (LTM) -21.10%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IDYA
Debt Ratio Lower is generally better. Negative is bad. 0.05
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.95

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IDYA
Trailing PE NM
Forward PE 4.65
P/S (TTM) 555.13
P/B 1.84
Price/FCF NM
EV/R 325.34
EV/Ebitda NM

FAQs

What is Ideaya Biosciences Inc share price today?

Ideaya Biosciences Inc (IDYA) share price today is $26.05

Can Indians buy Ideaya Biosciences Inc shares?

Yes, Indians can buy shares of Ideaya Biosciences Inc (IDYA) on Vested. To buy Ideaya Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IDYA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Ideaya Biosciences Inc be purchased?

Yes, you can purchase fractional shares of Ideaya Biosciences Inc (IDYA) via the Vested app. You can start investing in Ideaya Biosciences Inc (IDYA) with a minimum investment of $1.

How to invest in Ideaya Biosciences Inc shares from India?

You can invest in shares of Ideaya Biosciences Inc (IDYA) via Vested in three simple steps:

  • Click on Sign Up or Invest in IDYA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Ideaya Biosciences Inc shares
What is Ideaya Biosciences Inc 52-week high and low stock price?

The 52-week high price of Ideaya Biosciences Inc (IDYA) is $47.73. The 52-week low price of Ideaya Biosciences Inc (IDYA) is $24.71.

What is Ideaya Biosciences Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Ideaya Biosciences Inc (IDYA) is

What is Ideaya Biosciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Ideaya Biosciences Inc (IDYA) is 1.84

What is Ideaya Biosciences Inc dividend yield?

The dividend yield of Ideaya Biosciences Inc (IDYA) is 0.00%

What is the Market Cap of Ideaya Biosciences Inc?

The market capitalization of Ideaya Biosciences Inc (IDYA) is $2.18B

What is Ideaya Biosciences Inc’s stock symbol?

The stock symbol (or ticker) of Ideaya Biosciences Inc is IDYA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top